NEW YORK, June 6, 2017 /PRNewswire/ --
Today, DailyStockTracker.com concentrates on the Biotech
industry, which consists of companies engaged in the research and
development of new drugs, medical devices, and
procedures. Lined up for assessment this morning are: Cellect
Biotechnology Ltd (NASDAQ: APOP), BioDelivery Sciences
International Inc. (NASDAQ: BDSI), BioLine Rx Ltd (NASDAQ: BLRX),
and Benitec Biopharma Ltd (NASDAQ: BNTC). These free stocks reports
are currently available on DailyStockTracker.com. Simply sign up
for your complimentary member access at:
http://dailystocktracker.com/register/
Cellect Biotechnology
Kfar Saba, Israel-based Cellect
Biotechnology Ltd's stock finished Monday's session 2.84% lower at
$8.56 with a total trading volume of
27,234 shares. Over the previous three months and since the start
of this year, the Company's shares have advanced 34.80% and
177.02%, respectively. The stock is trading above its 200-day
moving average by 53.25%. Moreover, shares of Cellect Biotech,
which focuses on developing solutions for immune system
regeneration in Israel, have a
Relative Strength Index (RSI) of 34.93.
On May 23rd, 2017,
Cellect Biotech announced that David
Braun, Head of Merck Group's Medical Device Business, is
joining the Company's Scientific and Medical Advisory Board. Mr.
Braun has held multiple additional senior-level executive positions
at leading biotech and high-tech companies, ranging from global
Fortune 500 corporations to growth-oriented organizations,
including Biosafe S.A., a stem cell separation leader recently
acquired by GE, Newell Brands,
Logitech, Chiaro Networks, and Elbit Systems. Your complete
research report on APOP can be retrieved for free at:
http://dailystocktracker.com/registration/?symbol=APOP
BioDelivery Sciences
Shares in Raleigh, North
Carolina headquartered BioDelivery Sciences International
Inc. declined 4.26%, ending yesterday's session at $2.25 with a total trading volume of 405,472
shares. The stock has gained 25.00% in the past month, 9.76% in the
previous three months, and 28.57% on an YTD basis. The Company's
shares are trading 17.71% above their 50-day moving average and
8.95% above their 200-day moving average. Moreover, shares of
BioDelivery Sciences, which engages in the development and
commercialization of pharmaceutical products principally in the
areas of pain management and addiction, have an RSI of 56.49.
On May 26th, 2017,
research firm H.C. Wainwright initiated a 'Buy' rating on the
Company's stock, with a target price of $4 per share.
On June 01st, 2017,
BioDelivery Sciences announced that Dr. Mark A. Sirgo, President and CEO, will present
at the Jefferies 2017 Healthcare Conference on June 06th, 2017, at 9:30 a.m. ET
at the Grand Hyatt in New York
City. Dr. Sirgo will focus on progress with
commercialization efforts and strategic initiatives supporting
BELBUCA® (buprenorphine) buccal film (CIII), as well as
provide an update on BUNAVAIL® (buprenorphine and naloxone)
CIII. A free report on BDSI is just a click away at:
http://dailystocktracker.com/registration/?symbol=BDSI
BioLine Rx
On Monday, Jerusalem, Israel
headquartered BioLine Rx Ltd's stock saw a decline of 2.51%, to
close the day at $0.82. A total
volume of 177,369 shares was traded. The Company's shares are
trading 8.55% below their 50-day moving average. Additionally,
shares of BioLine Rx, which engages in identifying, in-licensing,
and developing therapeutic candidates that address unmet medical
needs, have an RSI of 41.26.
On May 18th, 2017,
research firm Maxim Group upgraded the Company's stock rating from
'Hold' to 'Buy' while revising its previous target price from
$1 a share to $3 a share.
On June 01st, 2017,
BioLine Rx announced that Genentech, a member of the Roche Group,
has filed a total of three, regulatory submissions required to
commence Phase-1b trials for BL-8040 in combination with
atezolizumab (Tecentriq®), Genentech's anti-PDL1 cancer
immunotherapy, for the treatment of patients with solid tumors. The
trials for pancreatic, gastric, and non-small cell cancer are
expected to commence during Q2 2017 after receipt of regulatory
approval. Sign up for your complimentary research report on BLRX
at: http://dailystocktracker.com/registration/?symbol=BLRX
Benitec Biopharma
Shares in North Sydney,
Australia headquartered Benitec Biopharma Ltd ended the day
4.02% lower at $2.39. A total volume
of 50,220 shares was traded. The stock has gained 56.21% since the
start of this year. The Company's shares are trading above their
200-day moving average by 16.27%. Furthermore, shares of Benitec
Biopharma, which develops treatments for chronic and
life-threatening human diseases based on its gene silencing
therapy, DNA-directed RNA interference in Australia, the UK, and the US, have an
RSI of 43.99. Register for free on DailyStockTracker.com and
download the latest research report on BNTC at:
http://dailystocktracker.com/registration/?symbol=BNTC
--
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. DST has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
DST has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer") represented by a
credentialed financial analyst [for further information on analyst
credentials, please email contact@dailystocktracker.com.
Rohit Tuli, a CFA® charterholder
(the "Sponsor"), provides necessary guidance in preparing the
document templates. The Reviewer has reviewed and revised the
content, as necessary, based on publicly available information
which is believed to be reliable. Content is researched, written
and reviewed on a reasonable-effort basis. The Reviewer has not
performed any independent investigations or forensic audits to
validate the information herein. The Reviewer has only
independently reviewed the information provided by the Author
according to the procedures outlined by DST. DST is not entitled to
veto or interfere in the application of such procedures by the
third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content
outside of this document has no association with the Author or the
Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any
error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is
accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. DST, the Author, and the
Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, DST, the Author, and the Reviewer do not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither DST nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://dailystocktracker.com/disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly.
If you're a company we are
covering and wish to no longer feature on our coverage list contact
us via email and/or phone between 09:30 EDT
to 16:00 EDT from Monday to Friday at:
Email: contact@dailystocktracker.com
Phone number: (207)-331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Chelmsford Park SA